Related references
Note: Only part of the references are listed.Disease-modifying treatments for multiple sclerosis - a review of approved medications
O. Torkildsen et al.
EUROPEAN JOURNAL OF NEUROLOGY (2016)
Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis
Jens Ingwersen et al.
NEUROTHERAPEUTICS (2016)
Incidence and prognosis of immune reconstitution inflammatory syndrome in HIV-associated progressive multifocal leucoencephalopathy
S. Sainz-de-la-Maza et al.
EUROPEAN JOURNAL OF NEUROLOGY (2016)
Progressive multifocal leukoencephalopathy and immune reconstitution inflammatory syndrome (IRIS)
Jan Bauer et al.
ACTA NEUROPATHOLOGICA (2015)
Lipid-Specific Immunoglobulin M Bands in Cerebrospinal Fluid Are Associated with a Reduced Risk of Developing Progressive Multifocal Leukoencephalopathy during Treatment with Natalizumab
Luisa M. Villar et al.
ANNALS OF NEUROLOGY (2015)
Case report of a patient with progressive multifocal leukoencephalopathy under treatment with dimethyl fumarate
Nele Dammeier et al.
BMC NEUROLOGY (2015)
Progressive multiple sclerosis
Daniel Ontaneda et al.
CURRENT OPINION IN NEUROLOGY (2015)
Treatment of progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome with intravenous immunoglobulin in a patient with multiple sclerosis treated with fingolimod after discontinuation of natalizumab
Z. Calic et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2015)
Progressive multifocal leukoencephalopathy after interferon beta-1a monotherapy
Helmar C. Lehmann et al.
JOURNAL OF NEUROLOGY (2015)
PML in a Patient without Severe Lymphocytopenia Receiving Dimethyl Fumarate
Dennis J. Nieuwkamp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
PML in a Patient with Lymphocytopenia Treated with Dimethyl Fumarate
Thorsten Rosenkranz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Progressive multifocal leukoencephalopathy: current treatment options and future perspectives
Dejan Pavlovic et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2015)
Immune system involvement in the pathogenesis of JC virus induced PML: what is learned from studies of patients with underlying diseases and therapies as risk factors
Maria Chiara G. Monaco et al.
FRONTIERS IN IMMUNOLOGY (2015)
B cells and progressive multifocal leukoencephalopathy: search for the missing link
Deniz Durali et al.
FRONTIERS IN IMMUNOLOGY (2015)
Immunreconstitution and Infectious Complications After Rituximab Treatment in Children and Adolescents: What Do We Know and What Can We Learn from Adults?
Jennifer Worch et al.
CANCERS (2015)
Sorting out the risks in progressive multifocal leukoencephalopathy
Leonard H. Calabrese et al.
NATURE REVIEWS RHEUMATOLOGY (2015)
Neuroimaging of Natalizumab Complications in Multiple Sclerosis: PML and Other Associated Entities
Justin M. Honce et al.
MULTIPLE SCLEROSIS INTERNATIONAL (2015)
Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis
Alberto Gajofatto et al.
DRUG HEALTHCARE AND PATIENT SAFETY (2015)
Anti-JC Virus Antibody Levels in Serum or Plasma Further Define Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
Tatiana Plavina et al.
ANNALS OF NEUROLOGY (2014)
Anti-JC virus (JCV) antibody prevalence in the JCV Epidemiology in MS (JEMS) trial
C. Bozic et al.
EUROPEAN JOURNAL OF NEUROLOGY (2014)
Maraviroc and JC Virus-Associated Immune Reconstitution Inflammatory Syndrome
Paul S. Giacomini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
JC virus antibody index in natalizumab-treated patients: correlations with John Cunningham virus DNA and C-reactive protein level
Roberta Lanzillo et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2014)
Outcome and survival of asymptomatic PML in natalizumab-treated MS patients
Tuan Dong-Si et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2014)
JC Virus Antibody Status Underestimates Infection Rates
Joseph R. Berger et al.
ANNALS OF NEUROLOGY (2013)
Human Polyomavirus Reactivation: Disease Pathogenesis and Treatment Approaches
Cillian F. De Gascun et al.
CLINICAL & DEVELOPMENTAL IMMUNOLOGY (2013)
L-Selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients
Nicholas Schwab et al.
NEUROLOGY (2013)
Alemtuzumab Therapy for Multiple Sclerosis
Alasdair J. Coles
NEUROTHERAPEUTICS (2013)
PML in a Patient Treated with Dimethyl Fumarate from a Compounding Pharmacy
Bob W. van Oosten et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Rituximab in Relapsing and Progressive Forms of Multiple Sclerosis: A Systematic Review
Tamara Castillo-Trivino et al.
PLOS ONE (2013)
Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis
Alessandra Lugaresi et al.
NEUROPSYCHIATRIC DISEASE AND TREATMENT (2013)
Therapeutic Decisions in Multiple Sclerosis Moving Beyond Efficacy
Wolfgang Brueck et al.
JAMA NEUROLOGY (2013)
Personalized medicine in multiple sclerosis: hope or reality?
Tobias Derfuss
BMC MEDICINE (2012)
Molecular Biology, Epidemiology, and Pathogenesis of Progressive Multifocal Leukoencephalopathy, the JC Virus-Induced Demyelinating Disease of the Human Brain
Michael W. Ferenczy et al.
CLINICAL MICROBIOLOGY REVIEWS (2012)
Natalizumab treatment perturbs memory- and marginal zone-like B-cell homing in secondary lymphoid organs in multiple sclerosis
Raquel Planas et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2012)
Case definition for progressive multifocal leukoencephalopathy following treatment with monoclonal antibodies
Dirk Mentzer et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2012)
NATALIZUMAB-ASSOCIATED PML IDENTIFIED IN THE PRESYMPTOMATIC PHASE USING MRI SURVEILLANCE
Nicholas F. Blair et al.
NEUROLOGY (2012)
Treatment-related progressive multifocal leukoencephalopathy: current understanding and future steps
Fariha Zaheer et al.
THERAPEUTIC ADVANCES IN DRUG SAFETY (2012)
The anti-inflammatory effects of dimethyl fumarate in astrocytes involve glutathione and haem oxygenase-1
Shao Xia Lin et al.
ASN NEURO (2011)
Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway
Ralf A. Linker et al.
BRAIN (2011)
Toxicities of Immunosuppressive Treatment of Autoimmune Neurologic Diseases
Enrico C. Lallana et al.
Current Neuropharmacology (2011)
Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis
B. Singer et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2011)
Progressive multifocal leukoencephalopathy
Robert Weissert
JOURNAL OF NEUROIMMUNOLOGY (2011)
Progressive multifocal leukoencephalopathy in an HIV patient receiving successful long-term HAART
Marta Mascarello et al.
JOURNAL OF NEUROVIROLOGY (2011)
Natalizumab and Progressive Multifocal Leukoencephalopathy
Clemens Warnke et al.
ARCHIVES OF NEUROLOGY (2010)
Dimethylfumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL-1β, TNF-α and IL-6 in an in-vitro model of brain inflammation
Henrik Wilms et al.
JOURNAL OF NEUROINFLAMMATION (2010)
Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis
Chen S. Tan et al.
LANCET NEUROLOGY (2010)
Incidence of progressive multifocal leukoencephalopathy in patients without HIV
K. L. Amend et al.
NEUROLOGY (2010)
Emerging Viral Infections of the Central Nervous System Part 2
Kenneth L. Tyler
ARCHIVES OF NEUROLOGY (2009)
Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project
Kenneth R. Carson et al.
BLOOD (2009)
Detection of JC Virus DNA and Proteins in the Bone Marrow of HIV-Positive and HIV-Negative Patients: Implications for Viral Latency and Neurotropic Transformation
Chen S. Tan et al.
JOURNAL OF INFECTIOUS DISEASES (2009)
PML-IRIS in patients with HIV infection Clinical manifestations and treatment with steroids
K. Tan et al.
NEUROLOGY (2009)
The bone marrow, B cells, and JC virus
Sidney A. Houff et al.
JOURNAL OF NEUROVIROLOGY (2008)
Progressive multifocal leukoencephalopathy in HIV-2-infected patient
Albane Bienaime et al.
AIDS (2006)
Changes in the natural history of progressive multifocal leukoencephalopathy in HIV-negative lymphoproliferative disorders:: Impact of novel therapies
J García-Suárez et al.
AMERICAN JOURNAL OF HEMATOLOGY (2005)
Brief report - Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease
G Van Assche et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Fulminant inflammatory leukoencephalopathy associated with HAART-induced immune restoration in AIDS-related progressive multifocal leukoencephalopathy
A Vendrely et al.
ACTA NEUROPATHOLOGICA (2005)
Progressive multifocal leukoencephalopathy in an HIV patient with normal CD4 T-cell count and magnetic resonance imaging
P Delobel et al.
AIDS (2004)
Dimethylfumarate is a potent inducer of apoptosis in human T cells
F Treumer et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2003)
Dimethylfumarate is an inhibitor of cytokine-induced nuclear translocation of NF-kappa B1, but not RelA in normal human dermal fibroblast cells
M Vandermeeren et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2001)
Share Paper
